Select Publications

Journal articles

Mukherjee T; Sakthivel R; Fong HY; McStea M; Chong ML; Omar SF; Chin AV; Kamaruzzaman S; Kamarulzaman A; Rajasuriar R; Cysique LA, 2018, 'Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia', AIDS and Behavior, 22, pp. 3226 - 3233, http://dx.doi.org/10.1007/s10461-018-2073-x

Wright EJ; Grund B; Robertson KR; Cysique L; Brew BJ; Collins GL; Poehlman-Roediger M; Vjecha MJ; Penalva De Oliveira AC; Standridge B; Carey C; Avihingsanon A; Florence E; Lundgren JD; Arenas-Pinto A; Mueller NJ; Winston A; Nsubuga MS; Lal L; Price RW, 2018, 'No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts', AIDS, 32, pp. 985 - 997, http://dx.doi.org/10.1097/QAD.0000000000001778

Bundell C; Brunt SJ; Cysique LA; Brusch A; Brew BJ; Price P, 2018, 'The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy', Pathology, 50, pp. 313 - 316, http://dx.doi.org/10.1016/j.pathol.2017.10.017

Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; De Wit J; Carr A, 2018, 'Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy', AIDS, 32, pp. 35 - 48, http://dx.doi.org/10.1097/QAD.0000000000001685

Cysique LA; Jugé L; Gates T; Tobia M; Moffat K; Brew BJ; Rae C, 2018, 'Covertly active and progressing neurochemical abnormalities in suppressed HIV infection', Neurology: Neuroimmunology and NeuroInflammation, 5, pp. &na, http://dx.doi.org/10.1212/NXI.0000000000000430

Cysique LA; Becker JT, 2017, 'HIV-related cognitive decline despite viral suppression and complex confounds in American women', Neurology, 89, pp. 1540 - 1541, http://dx.doi.org/10.1212/WNL.0000000000004503

Saloner R; Cysique LA, 2017, 'HIV-Associated neurocognitive disorders: A global perspective', Journal of the International Neuropsychological Society, 23, pp. 860 - 869, http://dx.doi.org/10.1017/S1355617717001102

Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA, 2017, 'Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure', Journal of Clinical and Experimental Neuropsychology, 39, pp. 753 - 767, http://dx.doi.org/10.1080/13803395.2016.1263282

Brew BJ; Cysique L, 2017, 'Does HIV prematurely age the brain?', The Lancet HIV, 4, pp. e380 - e381, http://dx.doi.org/10.1016/S2352-3018(17)30108-X

Cysique LA; Soares JR; Geng G; Scarpetta M; Moffat K; Green M; Brew BJ; Henry RG; Rae C, 2017, 'Erratum to: White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration (Journal of NeuroVirology, (2017), 23, 4, (539-547), 10.1007/s13365-017-0524-1)', Journal of NeuroVirology, 23, pp. 548 - 549, http://dx.doi.org/10.1007/s13365-017-0542-z

Cysique LA; Soares JR; Geng G; Scarpetta M; Moffat K; Green M; Brew BJ; Henry RG; Rae C, 2017, 'White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration', Journal of NeuroVirology, 23, pp. 539 - 547, http://dx.doi.org/10.1007/s13365-017-0524-1

Kamminga J; Lal L; Wright EJ; Bloch M; Brew BJ; Cysique LA, 2017, 'Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use', Current HIV/AIDS Reports, 14, pp. 83 - 92, http://dx.doi.org/10.1007/s11904-017-0349-9

Gott C; Gates T; Dermody N; Brew BJ; Cysique LA, 2017, 'Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity', PLOS ONE, 12, http://dx.doi.org/10.1371/journal.pone.0171887

Siefried KJ; Mao L; Kerr S; Cysique LA; Gates TM; McAllister J; Maynard A; De Wit J; Carr A, 2017, 'Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression', PLoS ONE, 12, pp. e0174613, http://dx.doi.org/10.1371/journal.pone.0174613

Cysique LA; Gott C; Gates TM; Dermody N; Brew BJ, 2017, 'Cognitive Change Trajectories in Virally Suppressed HIV-Infected Individuals Indicate High Prevalence of Disease Activity', PLoS One, 12, pp. e0171887, http://dx.doi.org/10.1371/journal.pone.0171887

Tobia M; Jones S; Lovelace M; Rae C; Cysique L; Brew B, 2016, 'Reduced cellular energy as a potential marker of HIV brain latency related neuropathogenesis: a pilot study', JOURNAL OF NEUROVIROLOGY, 22, pp. S76 - S77, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000394093700158&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bloch M; Kamminga J; Jayewardene A; Bailey M; Carberry A; Vincent T; Quan D; Maruff P; Brew B; Cysique LA, 2016, 'A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review', Clinical Infectious Diseases, 63, pp. 687 - 693, http://dx.doi.org/10.1093/cid/ciw399

Brunt SJ; Cysique LA; Lee S; Burrows S; Brew BJ; Price P, 2016, 'Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?', AIDS Research and Human Retroviruses, 32, pp. 567 - 572, http://dx.doi.org/10.1089/aid.2015.0328

Brouillette MJ; Yuen T; Fellows LK; Cysique LA; Heaton RK; Mayo NE, 2016, 'Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER cohort using group-based trajectory analysis', PLoS ONE, 11, pp. e0155766, http://dx.doi.org/10.1371/journal.pone.0155766

Gates TM; Cysique LA; Siefried KJ; Chaganti J; Moffat KJ; Brew BJ, 2016, 'Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder', AIDS, 30, pp. 591 - 600, http://dx.doi.org/10.1097/QAD.0000000000000951

Cysique LA; Dermody N; Carr A; Brew BJ; Teesson M, 2016, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, 22, pp. 56 - 65, http://dx.doi.org/10.1007/s13365-015-0368-5

Mayo NE; Brouillette M-J; Fellows LK, 2016, 'Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials', BMC NEUROLOGY, 16, http://dx.doi.org/10.1186/s12883-016-0527-1

Gates TM; Cysique LA, 2016, 'The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review', CNS Drugs, 30, pp. 53 - 69, http://dx.doi.org/10.1007/s40263-015-0302-7

Cysique LA, 2015, 'Advancing research in NeuroAIDS using collaboration and public data sharing', BMC Medical Genomics, 8, http://dx.doi.org/10.1186/s12920-015-0150-9

Lundgren JD; Babiker AG; Gordin F; Emery S; Grund B; Sharma S; Avihingsanon A; Cooper DA; Fätkenheuer G; Llibre JM; Molina JM; Munderi P; Schechter M; Wood R; Klingman KL; Collins S; Clifford Lane H; Phillips AN; Neaton JD; Kelleher A; Cysique L, 2015, 'Initiation of antiretroviral therapy in early asymptomatic HIV infection', New England Journal of Medicine, 373, pp. 795 - 807, http://dx.doi.org/10.1056/NEJMoa1506816

Cysique LA; Dermody N; Carr A; Brew BJ; Teesson M, 2015, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, http://dx.doi.org/10.1007/s13365-015-0368-5

Brew BJ; Robertson K; Wright EJ; Churchill M; Crowe SM; Cysique LA; Deeks S; Garcia JV; Gelman B; Gray LR; Johnson T; Joseph J; Margolis DM; Mankowski JL; Spencer B, 2015, 'HIV eradication symposium: will the brain be left behind?', Journal of NeuroVirology, 21, pp. 322 - 334, http://dx.doi.org/10.1007/s13365-015-0322-6

Cysique LA; Hey-Cunningham WJ; Dermody N; Chan P; Brew BJ; Koelsch KK, 2015, 'Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition', PLoS ONE, 10, pp. e0120488, http://dx.doi.org/10.1371/journal.pone.0120488

Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CSN; Davies NNWS; Price P; Brew BJ, 2015, 'APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - A cross-sectional observational study', BMC Neurology, 15, pp. 51, http://dx.doi.org/10.1186/s12883-015-0298-0

Wright EJ; Grund B; Cysique LA; Robertson KR; Brew BJ; Collins G; Shlay JC; Winston A; Read TRH; Price RW, 2015, 'Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial', HIV MEDICINE, 16, pp. 97 - 108, http://dx.doi.org/10.1111/hiv.12238

Cysique LA, 2015, 'Editorial commentary: Should longitudinal multisite studies become the new standard for investigating neurocognitive functions in HIV infection?', Clinical Infectious Diseases, 60, pp. 481 - 482, http://dx.doi.org/10.1093/cid/ciu863

Cysique LA; Gandevia SC, 2015, 'HIV infection and obstructive sleep apnea: Why epidemiological data are needed', Journal of Applied Physiology, 118, pp. 248 - 249, http://dx.doi.org/10.1152/japplphysiol.00989.2014

Cysique LA; Becker JT, 2015, 'Lessons to be learned from the largest study of cognition in American women with HIV disease', Neurology, 84, pp. 220 - 221, http://dx.doi.org/10.1212/WNL.0000000000001166

Sikkes S; Pera A; de Vries S; Maruff P; Cysique L; Bakardjian H; Dubois B; Scheltens P, 2015, 'O4‐10‐02: Cross‐cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire', Alzheimer's & Dementia, 11, http://dx.doi.org/10.1016/j.jalz.2015.07.400

Cysique LA; Koelsch KK, 2014, 'Primary HIV infection alters brain neurochemistry, but does antiretroviral treatment help?', Neurology, 83, pp. 1588 - 1589, http://dx.doi.org/10.1212/WNL.0000000000000947

Dwyer R; Wenhui L; Cysique L; Brew BJ; Lal L; Bain P; Wesselingh S; Wright EJ, 2014, 'Symptoms of depression and rates of neurocognitive impairment in HIV positive patients in Beijing, China', Journal of Affective Disorders, 162, pp. 89 - 95, http://dx.doi.org/10.1016/j.jad.2014.03.038

Cysique LA; Cysique LA; Heaton RK; Kamminga J; Lane T; Gates T; Moore DM; Hubner E; Carr A; Brew BJ, 2014, 'HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research', Journal of NeuroVirology, 20, pp. 258 - 268, http://link.springer.com/article/10.1007/s13365-014-0242-x

Lu GM; Brew BJ; Siefried KJ; Draper B; Cysique LA, 2014, 'Is the HIV dementia scale a reliable tool for assessing HIV-relatedneurocognitive decline?', Journal of AIDS and Clinical Research, 5, http://dx.doi.org/10.4172/2155-6113.1000269

Cysique LA; Brew BJ, 2014, 'The effects of HIV and aging on brain functions: Proposing a research framework and update on last 3 years' findings', Current Opinion in HIV and AIDS, 9, pp. 355 - 364, http://dx.doi.org/10.1097/COH.0000000000000078

Cysique LA; Heaton RK; Kamminga J; Lane T; Gates TM; Moore DM; Hubner E; Carr A; Brew BJ, 2014, 'HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research', Journal of NeuroVirology, 20, pp. 258 - 268, http://dx.doi.org/10.1007/s13365-014-0242-x

Mayer KH; Zanoni BC, 2013, 'HIV Chemoprophylaxis for Adolescents: Educable Moment, Not Magic Bullet', CLINICAL INFECTIOUS DISEASES, 56, pp. 1156 - 1158, http://dx.doi.org/10.1093/cid/cis1026

Wiley CA; Cysique LA, 2013, 'The cost of silencing HIV in the brain', Neurology, 80, pp. 1363 - 1364, http://dx.doi.org/10.1212/WNL.0b013e31828c3077

Antinori A; Arendt G; Grant I; Letendre S; Muñoz-Moreno JA; Eggers C; Brew B; Brouillette MJ; Bernal-Cano F; Carvalhal A; Christo PP; Cinque P; Cysique L; Ellis R; Everall I; Gasnault J; Husstedt I; Korten V; Machala L; Obermann M; Ouakinin S; Podzamczer D; Portegies P; Rackstraw S; Rourke S; Sherr L; Streinu-Cercel A; Winston A; Wojna V; Yazdanpannah Y; Arbess G; Baril JG; Begovac J; Bergin C; Bonfanti P; Bonora S; Brinkman K; Canestri A; Cholewinska-Szymanska G; Chowers M; Cooney J; Corti M; Doherty C; Elbirt D; Esser S; Florence E; Force G; Gill J; Goffard JC; Harrer T; Li P; Van De Kerckhove L; Knecht G; Matsushita S; Matulionyte R; McConkey S; Mouglignier A; Oka S; Penalva A; Riesenberg K; Sambatakou H; Tozzi V; Vassallo M; Wetterberg P; Drapato AW, 2013, 'Assessment, diagnosisand treatment of Human Immunodeficiency Virus (HIV)-associated neurocognitive disorders (HAND): A consensus report of the mind exchange program', Clinical Infectious Diseases, 56, pp. 1004 - 1017, http://dx.doi.org/10.1093/cid/cis975

Cysique LA; Moffat K; Moore DM; Lane TA; Davies NWS; Carr AD; Brew BJ; Rae CD, 2013, 'HIV, Vascular and Aging Injuries in the Brain of Clinically Stable HIV-Infected Adults: A 1H MRS Study', PLoS One, 8, pp. Article numbere61738, http://dx.doi.org/10.1371/journal.pone.0061738

Kamminga J; Cysique LA; Lu G; Batchelor J; Brew BJ, 2013, 'Validity of Cognitive Screens for HIV-Associated Neurocognitive Disorder: A Systematic Review and an Informed Screen Selection Guide', Current HIV/AIDS Reports, 10, pp. 342 - 355, http://dx.doi.org/10.1007/s11904-013-0176-6

Cysique L; Brew B, 2012, 'Characteristics of neurocognitive decline in virally-suppressed middle-aged HIV plus individuals', JOURNAL OF NEUROVIROLOGY, 18, pp. 26 - 26, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000304487800054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chew C; Cysique L; Brew B; Price P, 2012, 'Relationships between genetic markers of neuroinflammation, neurodegeneration and neurocognitive impairment in controlled HIV infection', JOURNAL OF NEUROVIROLOGY, 18, pp. 23 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000304487800048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee JM; Ramos EM; Lee JH; Gillis T; Mysore JS; Hayden MR; Warby SC; Morrison P; Nance M; Ross CA; Margolis RL; Squitieri F; Orobello S; Di Donato S; Gomez-Tortosa E; Ayuso C; Suchowersky O; Trent RJA; McCusker E; Novelletto A; Frontali M; Jones R; Ashizawa T; Frank S; Saint-Hilaire MH; Hersch SM; Rosas HD; Lucente D; Harrison MB; Zanko A; Abramson RK; Marder K; Sequeiros J; Paulsen JS; Landwehrmeyer GB; Myers RH; MacDonald ME; Gusella JF, 2012, 'CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion', Neurology, 78, pp. 690 - 695, http://dx.doi.org/10.1212/WNL.0b013e318249f683

Perez-Valero I; Cysique L; Letendre S; Heaton R, 2012, 'Comments to Garvey et al.: "low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy"', HIV Clinical Trials, 13, pp. 296 - 298, http://dx.doi.org/10.1310/hct1305-296

Cruse B; Cysique LA; Markus R; Brew BJ, 2012, 'Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy', Journal of Neurovirology, 18, pp. 264 - 276, http://dx.doi.org/10.1007/s13365-012-0092-3


Back to profile page